DataMEDS AI enters unapproved peptide market

Tampa-based DataMEDS AI moved into a contested segment of the prescription drug market on Monday, announcing a supply agreement for six experimental peptides that lack Food and Drug Administration approval. The Nasdaq-listed company plans to begin filling prescriptions through its subsidiary, Corexa Health, within days. This rapid entry coincides with a federal policy shift that allows licensed pharmacies to compound specific substances while the FDA continues its review process.

The company secured access to BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. These short chains of amino acids have attracted interest for treating inflammation, tissue damage, obesity, and neurological conditions. None of the six ingredients have been evaluated by the FDA for safety or effectiveness. The U.S. Department of Health and Human Services issued a policy change on Oct. 30 that establishes a limited path for compounding these specific compounds.

Gerald Commissiong, the company’s interim co-CEO, stated that the firm aims to shift customers from online research-use channels into conventional prescription systems. He noted that many patients currently buying these substances under gray market labels would prefer to purchase them from a licensed pharmacy. Under the new arrangement, physicians can prescribe compounded preparations, and pharmacists can dispense them according to federal and state requirements.

DataMEDS, formerly Wellgistics Health, will manage the distribution from a warehouse in Lakeland. The firm intends to handle supplies from manufacturers and distribute ingredients to its network of more than 6,500 independent pharmacies. The company plans to use its Health Lives Here mobile application to collect and report safety information. However, the announcement did not specify how many pharmacies will purchase the ingredients or how many prescriptions they expect to fill.

The FDA’s Pharmacy Compounding Advisory Committee examined these substances during meetings on July 23 and 24. The committee reviewed proposed uses for wound healing, inflammatory conditions, obesity, insomnia, and neurological disorders. Those applications remain unproven. Participating pharmacies must meet strict requirements for ingredient sourcing, testing, patient-specific prescriptions, and adverse event reporting.

The HHS policy does not grant full FDA approval, and federal officials retain the ability to change or withdraw the rules at any time. DataMEDS has not disclosed the financial terms of the supply agreement, the identity of its supplier, or the expected revenue from the arrangement. The November rollout operates through Corexa Pharmacy, a division of a healthcare group that also includes pharmaceutical distribution, technology platforms, and a clinical diagnostics laboratory in Pittsburgh.